Suchergebnisse - "Subbiah, Vivek"

PubPharm (44)

1

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers : the RE-RAFFLE study

enthalten in: Molecular cancer | 2024

von Nelson, B. | Roszik, J. | Ahmed, J. | +11

2

Targeting All BRAF Alterations : The (Re)-Search Continues

enthalten in: JCO precision oncology | 2024

von Bhamidipati, D. | Pellatt, A. | Subbiah, V.

3

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

enthalten in: Cancer research communications | 2024

von Subbiah, V. | Coleman, N. | Piha-Paul, S. | +15

4

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers : the phase 2 ROAR trial

enthalten in: Nature medicine | 2023

von Subbiah, V. | Kreitman, R. | Wainberg, Z. | +20

CommentIn: Nat Rev Clin Oncol. 2023 Jul;20(7):425. - PMID 37169890

5

Expanding the Benefit : Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors

enthalten in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting | 2023

von Gouda, M. | Subbiah, V.

6

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer : A Single-Center Retrospective Cohort Study

enthalten in: Thyroid : official journal of the American Thyroid Association | 2023

von Zhao, X. | Wang, J. | Dadu, R. | +20

CommentIn: Thyroid. 2023 Apr;33(4):402-403. - PMID 36856459

7

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia

enthalten in: Blood | 2023

von Kreitman, R. | Moreau, P. | Ravandi, F. | +14

CommentIn: Blood. 2023 Mar 2;141(9):965-966. - PMID 36862436

8

Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors

enthalten in: JCO precision oncology | 2022

von Dankner, M. | Wang, Y. | Fazelzad, R. | +26

9

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors

enthalten in: Molecular cancer therapeutics | 2022

von Adashek, J. | Menta, A. | Reddy, N. | +3

10

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR) : a multicentre, open-label, single-arm, phase 2, basket trial

enthalten in: The Lancet. Oncology | 2022

von Wen, P. | Stein, A. | van den Bent, M. | +23

CommentIn: Lancet Oncol. 2022 Jan;23(1):3-4. - PMID 34838157

1
2
3
4
5
Nächster »
[5]